Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) EBIT: 2016-2024

Historic EBIT for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$129.7 million.

  • Solid Biosciences' EBIT fell 79.19% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 24.44%. This contributed to the annual value of -$129.7 million for FY2024, which is 24.44% down from last year.
  • Latest data reveals that Solid Biosciences reported EBIT of -$129.7 million as of FY2024, which was down 24.44% from -$104.3 million recorded in FY2023.
  • In the past 5 years, Solid Biosciences' EBIT registered a high of -$72.3 million during FY2021, and its lowest value of -$129.7 million during FY2024.
  • In the last 3 years, Solid Biosciences' EBIT had a median value of -$106.5 million in 2022 and averaged -$113.5 million.
  • Its EBIT has fluctuated over the past 5 years, first grew by 25.91% in 2020, then slumped by 47.33% in 2022.
  • Solid Biosciences' EBIT (Yearly) stood at -$88.4 million in 2020, then increased by 18.27% to -$72.3 million in 2021, then plummeted by 47.33% to -$106.5 million in 2022, then grew by 2.07% to -$104.3 million in 2023, then declined by 24.44% to -$129.7 million in 2024.